European Biotech Acquisition Corp. (EBACU) Prices Upsized $120M IPO

European Biotech Acquisition Corp. announced the pricing of its $120 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “EBACU,” Tuesday, March 16.

The new company aims to combine with a European life sciences target with a focus on those nearing potential breakthroughs. European Biotech is led by CEO Eduardo Bravo Fernandez de Araoz and CFO Koen Sintnicolaas.

Total SPAC deal count for 2021 year-to-date is now 254. This offering is expected to close on Thursday, March 18.

Credit Suisse Securities (USA) LLC and Kempen & Co U.S.A. are serving as the joint book-running managers for this offering. Davis Polk & Wardwell LLP is serving as Issuer’s Counsel with Shearman & Sterling LLP serving as Underwriter’s Counsel. Marcum LLP serves as auditor. Continental Stock Transfer & Trust Company is acting as trustee.